The European Commission opened a public consultation to help it develop the Health Emergency Preparedness and Response Authority, a new initiative to better prepare Europe for cross-border health threats.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AB Science, Amarin, Ampio, Ani, Boehringer, Catalent, Checkmate, Hoth, Janssen, Kuros, Ionis, Maxwell, Moderna, Ose, Oryzon, Oxford Biomedica, Progenity, Rational Vaccines, Valeo, Yumanity.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Baebies, Compleware, Cyduct, Dexcom, Eyekor, Welldoc.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 89bio, Abbvie, Acadia, Exelixis, Eli Lilly, Passage, Supernus, Tetra.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acea, Advaxis, Amneal, Anixa, Can-Fite, Chinook, Emergent, Johnson & Johnson, Kashiv, Ontochem, Panacea, Sairopa, Sorrento, Teneobio, Vir, Virpax.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aeon, Bio-Path, Corbus, Fibrogen, Innovation, Ionis, Teneobio, Uniqure.
The latest global regulatory news, changes and updates affecting biopharma, including: First thrombosis incident reported in Australia; FDA offers guidance on ANDAs during pandemic; FDA revises Moderna EUA; Fed Circuit’s indefinite ruling stands; BMS settles Medicaid rebate claims; GAO refuses to reconsider VA challenge.
Following the company’s COVID-19 manufacturing misstep, Emergent Biosolutions Inc. continued its struggle to rebalance as top-line data from a phase III study it participated in failed to hit its primary endpoints with statistically significant results. The data showed that adding anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days failed to provide clinical benefit when compared to standard of care plus placebo. The global, multicenter double-blind, placebo-controlled randomized study assessed the safety and efficacy of four immunoglobulin candidates, the SARS-CoV-2 immune globulin intravenous (human) (COVID-HIG) plus standard of care.
LONDON – The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) stood by its view that the benefits of Astrazeneca plc’s COVID-19 vaccine “continue to outweigh the risks,” as it published the latest summary of reported adverse events.
RSS
